Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy

Anne Grosen; Emanuelle Bellaguarda; Ingela Liljeqvist-Soltic; Mette Mejlby Hansen; Anne-Bine Skytte; Mette Julsgaard; Stephen B Hanauer; Jens Kelsen

doi:10.1093/ibd/izac028

Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy

Inflamm Bowel Dis. 2022 Oct 3;28(10):1603-1606. doi: 10.1093/ibd/izac028.

Authors

Anne Grosen¹, Emanuelle Bellaguarda², Ingela Liljeqvist-Soltic³, Mette Mejlby Hansen¹, Anne-Bine Skytte⁴, Mette Julsgaard¹, Stephen B Hanauer², Jens Kelsen¹

Affiliations

¹ Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
² Division of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
³ Reproductive Medicine Centre, Skaane University Hospital, Malmoe, Sweden.
⁴ Cryos International, Aarhus, Denmark.

PMID: 35212374
DOI: 10.1093/ibd/izac028

No abstract available

Keywords: inflammatory bowel disease; sperm DNA integrity; ustekinumab.

Plain language summary

We demonstrate that ustekinumab does not adversely affect semen quality or sex hormones in male patients. Ustekinumab is not detectable in semen and poses no risk to partners. Our observations support a recommendation to continue ustekinumab therapy in patients wishing to conceive.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

DNA
Humans
Inflammatory Bowel Diseases* / drug therapy
Male
Semen
Spermatozoa
Ustekinumab* / therapeutic use

Substances

DNA
Ustekinumab